REG - Burning Rock Biotech - BNR Announces Expected Delisting of ADS

Burning Rock BiotechAnnouncement

19/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240819:nRSS8969Aa&default-theme=true

RNS Number : 8969A  Burning Rock Biotech Limited  19 August 2024

 

 

Burning Rock Biotech Limited Announces Expected Delisting of American
Depositary Shares

 

Burning Rock Biotech Limited (the "Company" or "Burning Rock") announces that,
on August 19, 2024, it intends to submit requests (a) to the London Stock
Exchange (the "LSE"), to cancel the admission to trading on the Main Market of
its American Depositary Shares representing the class A ordinary shares of the
Company (the "ADSs"), and (b) to the UK Financial Conduct Authority, to cancel
the listing of the ADSs on the Official List.

 

As a result of sustained low volume of trading and liquidity in the ADSs on
the LSE, and taking into account the costs associated with maintaining such
listing in place, the Company is seeking the delisting and cancellation of
admission to trading of the ADSs from the LSE (the "Delisting"). It is
anticipated that the Delisting will take effect on or about September 18,
2024.

 

Following the Delisting, the ADSs will continue to trade on the Nasdaq Global
Market.

 

About Burning Rock

 

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to
Guard Life via Science, focuses on the application of next generation
sequencing (NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage cancer
patients, and ii) NGS-based cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.

 

For more information about Burning Rock, please visit: www.brbiotech.com.

 

Contact: IR@brbiotech.com

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DOCEASPNFLKLEEA